AZNCF News and Press, AstraZeneca Plc From 06/24/22

At the ASCO meeting, BioNTech presented phase-1 clinical trial data for its mRNA-based vaccine for pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. AstraZeneca and Daiichi presented data for the Destiny-Breast04 trial, which tested Enhertu against chemother...

Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...

BDJ’s yield is quite high as compared to average income funds, and a minimum positive price growth will generate double-digit returns. Due to its deep diversification, BDJ is in a position to absorb the sectorial risks that have begun due to economic uncertainty. Due to a h...

Vivo Capital, a US-China healthcare investor, held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerati...

The Carillon Family of Funds spans a range of investment objectives and asset classes designed for long-term investors. Along with the spike in oil prices, energy stocks performed best during the quarter, followed by more defensive and countercyclical sectors like utilities and consum...

Lexicon has not been lucky with the FDA. However, there are reasons, discussed below, which make me see a special situation here. It may not be a bad idea to take the plunge. For further details see: Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shar...

Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund (the “Fund”) declined 14.64% (Institutional Shares) during the first quarte...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2022 Q1 earnings call. For further details see: AstraZeneca PLC 2022 Q1 - Results - Earnings Call Presentation